Germany's Health Ministry has proposed a two-stage AMNOG pathway that would allow selected medicines to receive an initial benefit assessment on the best available evidence, followed by reassessment after further evidence has been generated.
France has agreed a new medicines pricing framework that combines more favourable launch pricing for selected innovative products with earlier and more systematic price reviews over the product lifecycle.
France will stop reimbursing low-clinical-benefit medicines at 100% solely because they are prescribed for a long-term condition, leaving the standard 15% reimbursement rate to apply from October.
The Council has formally adopted the agreed EU pharmaceutical package, preserving the March compromise while moving major changes to regulatory protection, orphan incentives and generic entry towards final approval.
AIFA reports a €950.6 million overspend on medicines bought directly by public healthcare structures in the first two months of 2026, with the underlying expenditure rate still close to that recorded in 2025.
Scotland has allocated £12.1 million of VPAG investment funding to clinical research and HTA improvement, giving the UK-wide programme specific 2026–27 spending commitments.
Armenia’s new universal health insurance system now covers 1.815 million people, with around 850,000 already receiving insured healthcare services or medicines.
Five Nordic purchasing organisations are preparing a broader joint tender for intravenous medicines, extending existing Denmark–Norway–Iceland cooperation to include purchasers in Sweden and Finland.
A third EU JCA has been stopped for dossier non-compliance, with the sintilimab case showing how incomplete documentation of indirect comparisons can end the assessment and reopen national evidence requests.
Greece proposes to give therapeutic value a more direct role in medicine price negotiations, reimbursement prioritisation and exceptional negotiations for public-health reasons.
Moldova has proposed a wider temporary-access framework for unregistered medicines, including accelerated routes for urgent treatment, hospital therapies, shortages and last-resort programmes.
Lithuania is asking companies to pre-notify planned reimbursement applications so that medicines HTA work can be scheduled more evenly and assessment delays reduced.
Switzerland's Parliament has instructed the government to develop a broader route for healthcare providers to import generics from abroad and have them reimbursed by mandatory health insurance.
The EU HTA Coordination Group has introduced standard written-input templates for patients, carers and clinicians, giving stakeholder evidence a more consistent place in JCA scoping and report review.
The Danish Medicines Council will add a dedicated patient-perspective section to medicine assessment reports, making patient evidence more systematic and visible in its decision-making record.
Spain's Medicines and Medical Devices Bill has entered formal parliamentary scrutiny, preserving the July access and dynamic-pricing reforms while making the proposed statutory decision timelines and post-exclusivity pricing mechanism more explicit.
Czech reimbursement forms now record the status of EU Joint Clinical Assessment, bringing the new European HTA process into routine national reimbursement administration.
AIFA reimbursed 323 medicines in 2025, a 42% increase from 2024, alongside further evidence that the post-reform organisation is processing pricing and reimbursement procedures more quickly.
HERA has set out three EU-level purchasing routes for medical countermeasures, clarifying how demand can be aggregated and when centralised or exclusive negotiation may be used.
